


9-26-3

AK/1.6 GO



Attorney Docket No.: 5700.240-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: Jeppesen et al.

Serial No.: 09/994,971

Group Art Unit: 1624

Filed: November 27, 2001

Examiner: Tamthom Ngo Truong

For: Tricyclic Compounds as Nuclear Receptor Modulators (amended)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment/Response

is being deposited with the United States Postal Service as Express Mail Label No. EV 246877571 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On September 25, 2003

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)

Serial Number 09/994,971
Express Mail Number: EV 246877571 US
Inventor: Jeppesen et al.

Attorney Docket No.: 5700.240-US

RECEIVED
OCT 01 2003
PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 09/994,971

Group Art Unit: 1624

Filed: November 27, 2001

Examiner: Truong, Tamthom Ngo

For: Tricyclic Compounds as Nuclear Receptor Modulators

AMENDMENT/ RESPONSE

Assistant Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is submitted in response to the final Office Action on the merits mailed June 25, 2003, having a shortened statutory period for reply set to expire September 25, 2003, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Claims numbered 1, 2, 7, 16, 18, 23, 24, 26-33, 36, 43, 44, and 50-55 are pending in the application. Claims numbered 1, 2, 7, 16, 18, 23, 24, 26-33, 36, 43, 44, and 50-55 have been rejected by the Examiner.

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this amendment/response, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk Pharmaceuticals, Inc., for any such required fee.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application, with current amendments noted.

Serial Number 09/994,971
Express Mail Number: EV 246877571 US
Inventor: Jeppesen et al.

Claim number 1 has been amended. The specification has been amended. No new matter has been introduced by this amendment.